-
1
-
-
0021345180
-
Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients
-
Prentice HG, Blacklock HA, Janossy G, et al. Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet. 1984; 1: 472-6.
-
(1984)
Lancet
, vol.1
, pp. 472-476
-
-
Prentice, H.G.1
Blacklock, H.A.2
Janossy, G.3
-
2
-
-
0016860720
-
Bone-marrow transplantation (second of two parts)
-
Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975; 292: 895-902.
-
(1975)
N Engl J Med
, vol.292
, pp. 895-902
-
-
Thomas, E.D.1
Storb, R.2
Clift, R.A.3
-
3
-
-
0021296674
-
Graft-versus-host disease: pathophysiological and clinical aspects
-
Deeg HJ, Storb R. Graft-versus-host disease: pathophysiological and clinical aspects. Annu Rev Med. 1984; 35: 11-24.
-
(1984)
Annu Rev Med
, vol.35
, pp. 11-24
-
-
Deeg, H.J.1
Storb, R.2
-
4
-
-
0025963233
-
Graft-versus-host disease
-
Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med. 1991; 324: 667-74.
-
(1991)
N Engl J Med
, vol.324
, pp. 667-674
-
-
Ferrara, J.L.1
Deeg, H.J.2
-
5
-
-
0030006681
-
Bone marrow transplantation from unrelated donors
-
Gajewski J, Champlin R. Bone marrow transplantation from unrelated donors. Curr Opin Oncol. 1996; 8: 84-8.
-
(1996)
Curr Opin Oncol
, vol.8
, pp. 84-88
-
-
Gajewski, J.1
Champlin, R.2
-
6
-
-
0035100518
-
Acute graft-vs-host disease: pathobiology and management
-
Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol. 2001; 29: 259-77.
-
(2001)
Exp Hematol
, vol.29
, pp. 259-277
-
-
Goker, H.1
Haznedaroglu, I.C.2
Chao, N.J.3
-
7
-
-
0035058630
-
New therapeutic modalities in the treatment of graft-versus-host disease
-
Basara N, Kiehl MG, Fauser AA. New therapeutic modalities in the treatment of graft-versus-host disease. Crit Rev Oncol Hematol. 2001; 38: 129-38.
-
(2001)
Crit Rev Oncol Hematol
, vol.38
, pp. 129-138
-
-
Basara, N.1
Kiehl, M.G.2
Fauser, A.A.3
-
8
-
-
0027365965
-
Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
-
Chao NJ, Schmidt GM, Niland JC, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993; 329: 1225-30.
-
(1993)
N Engl J Med
, vol.329
, pp. 1225-1230
-
-
Chao, N.J.1
Schmidt, G.M.2
Niland, J.C.3
-
9
-
-
77951075744
-
Management of acute graft-versus-host disease in children
-
Carpenter PA, Macmillan ML. Management of acute graft-versus-host disease in children. Pediatr Clin North Am. 2010; 57: 273-95.
-
(2010)
Pediatr Clin North Am
, vol.57
, pp. 273-295
-
-
Carpenter, P.A.1
Macmillan, M.L.2
-
10
-
-
1542787424
-
Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review
-
Weisdorf DJ, Hurd D, Carter S, et al. Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review. Biol Blood Marrow Transplant. 2003; 9: 512-8.
-
(2003)
Biol Blood Marrow Transplant
, vol.9
, pp. 512-518
-
-
Weisdorf, D.J.1
Hurd, D.2
Carter, S.3
-
11
-
-
84855376470
-
Clinical applications for biomarkers of acute and chronic graft-versus-host disease
-
Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2012; 18: S116-24.
-
(2012)
Biol Blood Marrow Transplant
, vol.18
-
-
Levine, J.E.1
Paczesny, S.2
Sarantopoulos, S.3
-
13
-
-
23744458895
-
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study
-
Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005; 106: 1495-500.
-
(2005)
Blood
, vol.106
, pp. 1495-1500
-
-
Cahn, J.Y.1
Klein, J.P.2
Lee, S.J.3
-
14
-
-
8544247155
-
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade
-
Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997; 97: 855-64.
-
(1997)
Br J Haematol
, vol.97
, pp. 855-864
-
-
Rowlings, P.A.1
Przepiorka, D.2
Klein, J.P.3
-
15
-
-
0016187133
-
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
-
Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18: 295-304.
-
(1974)
Transplantation
, vol.18
, pp. 295-304
-
-
Glucksberg, H.1
Storb, R.2
Fefer, A.3
-
16
-
-
30344461633
-
Pathophysiology of graft-versus-host disease
-
Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006; 43: 3-10.
-
(2006)
Semin Hematol
, vol.43
, pp. 3-10
-
-
Ferrara, J.L.1
Reddy, P.2
-
17
-
-
0034193057
-
The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation
-
Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000; 95: 2754-9.
-
(2000)
Blood
, vol.95
, pp. 2754-2759
-
-
Hill, G.R.1
Ferrara, J.L.2
-
18
-
-
0142025571
-
The pathophysiology of acute graft-versus-host disease
-
Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003; 78: 181-7.
-
(2003)
Int J Hematol
, vol.78
, pp. 181-187
-
-
Ferrara, J.L.1
Cooke, K.R.2
Teshima, T.3
-
19
-
-
4444257679
-
Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies
-
Zeiser R, Marks R, Bertz H, et al. Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol. 2004; 83: 551-65.
-
(2004)
Ann Hematol
, vol.83
, pp. 551-565
-
-
Zeiser, R.1
Marks, R.2
Bertz, H.3
-
20
-
-
80052493237
-
Danger signals activating innate immunity in graft-versus-host disease
-
Zeiser R, Penack O, Holler E, et al. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med. 2011; 89: 833-45.
-
(2011)
J Mol Med
, vol.89
, pp. 833-845
-
-
Zeiser, R.1
Penack, O.2
Holler, E.3
-
21
-
-
10344261473
-
Genetic polymorphisms predicting the outcome of bone marrow transplants
-
Dickinson AM, Middleton PG, Rocha V, et al. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br J Haematol. 2004; 127: 479-90.
-
(2004)
Br J Haematol
, vol.127
, pp. 479-490
-
-
Dickinson, A.M.1
Middleton, P.G.2
Rocha, V.3
-
22
-
-
2442704411
-
Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
-
Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol. 2004; 22: 1696-705.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1696-1705
-
-
Bader, P.1
Kreyenberg, H.2
Hoelle, W.3
-
23
-
-
0022640843
-
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
-
Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986; 136: 2348-57.
-
(1986)
J Immunol
, vol.136
, pp. 2348-2357
-
-
Mosmann, T.R.1
Cherwinski, H.2
Bond, M.W.3
-
24
-
-
0027323622
-
Critical role of interleukin-2 in the development of acute graft-versus-host disease
-
Via CS, Finkelman FD. Critical role of interleukin-2 in the development of acute graft-versus-host disease. Int Immunol. 1993; 5: 565-72.
-
(1993)
Int Immunol
, vol.5
, pp. 565-572
-
-
Via, C.S.1
Finkelman, F.D.2
-
25
-
-
0025329036
-
A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease
-
Anasetti C, Martin PJ, Hansen JA, et al. A phase I-II study evaluating the murine anti-IL-2 receptor antibody 2A3 for treatment of acute graft-versus-host disease. Transplantation. 1990; 50: 49-54.
-
(1990)
Transplantation
, vol.50
, pp. 49-54
-
-
Anasetti, C.1
Martin, P.J.2
Hansen, J.A.3
-
26
-
-
0027956688
-
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor
-
Anasetti C, Hansen JA, Waldmann TA, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994; 84: 1320-7.
-
(1994)
Blood
, vol.84
, pp. 1320-1327
-
-
Anasetti, C.1
Hansen, J.A.2
Waldmann, T.A.3
-
27
-
-
0033964862
-
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
-
Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000; 95: 83-9.
-
(2000)
Blood
, vol.95
, pp. 83-89
-
-
Przepiorka, D.1
Kernan, N.A.2
Ippoliti, C.3
-
28
-
-
0030861750
-
Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines
-
Hill GR, Crawford JM, Cooke KR, et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997; 90: 3204-13.
-
(1997)
Blood
, vol.90
, pp. 3204-3213
-
-
Hill, G.R.1
Crawford, J.M.2
Cooke, K.R.3
-
29
-
-
0032717103
-
Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia
-
Hill GR, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999; 104: 459-67.
-
(1999)
J Clin Invest
, vol.104
, pp. 459-467
-
-
Hill, G.R.1
Teshima, T.2
Gerbitz, A.3
-
30
-
-
10744228197
-
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation
-
Mullighan C, Heatley S, Doherty K, et al. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation. 2004; 77: 587-96.
-
(2004)
Transplantation
, vol.77
, pp. 587-596
-
-
Mullighan, C.1
Heatley, S.2
Doherty, K.3
-
31
-
-
84983719872
-
Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation
-
Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med. 2003; 349: 2201-10.
-
(2003)
N Engl J Med
, vol.349
, pp. 2201-2210
-
-
Lin, M.T.1
Storer, B.2
Martin, P.J.3
-
32
-
-
0023840014
-
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials
-
Storb R, Deeg HJ, Fisher L, et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood. 1988; 71: 293-8.
-
(1988)
Blood
, vol.71
, pp. 293-298
-
-
Storb, R.1
Deeg, H.J.2
Fisher, L.3
-
33
-
-
0022470379
-
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
-
Storb R, Deeg HJ, Farewell V, et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986; 68: 119-25.
-
(1986)
Blood
, vol.68
, pp. 119-125
-
-
Storb, R.1
Deeg, H.J.2
Farewell, V.3
-
34
-
-
0034909687
-
Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation
-
Hiraoka A, Ohashi Y, Okamoto S, et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001; 28: 181-5.
-
(2001)
Bone Marrow Transplant
, vol.28
, pp. 181-185
-
-
Hiraoka, A.1
Ohashi, Y.2
Okamoto, S.3
-
35
-
-
0034665674
-
Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
-
Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000; 96: 2062-8.
-
(2000)
Blood
, vol.96
, pp. 2062-2068
-
-
Nash, R.A.1
Antin, J.H.2
Karanes, C.3
-
36
-
-
0022624255
-
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
-
Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986; 314: 729-35.
-
(1986)
N Engl J Med
, vol.314
, pp. 729-735
-
-
Storb, R.1
Deeg, H.J.2
Whitehead, J.3
-
37
-
-
10344238083
-
FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors
-
Nash RA, Pineiro LA, Storb R, et al. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood. 1996; 88: 3634-41.
-
(1996)
Blood
, vol.88
, pp. 3634-3641
-
-
Nash, R.A.1
Pineiro, L.A.2
Storb, R.3
-
38
-
-
77953959027
-
High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation
-
Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010; 47: 65-77.
-
(2010)
Immunol Res
, vol.47
, pp. 65-77
-
-
Luznik, L.1
Fuchs, E.J.2
-
39
-
-
80051634380
-
Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy
-
Laskin BL, Goebel J, Davies SM, et al. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011; 118: 1452-62.
-
(2011)
Blood
, vol.118
, pp. 1452-1462
-
-
Laskin, B.L.1
Goebel, J.2
Davies, S.M.3
-
40
-
-
0037669432
-
Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
-
Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003; 122: 128-34.
-
(2003)
Br J Haematol
, vol.122
, pp. 128-134
-
-
Wong, R.1
Beguelin, G.Z.2
de Lima, M.3
-
41
-
-
20244362642
-
Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens
-
Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005; 11: 383-8.
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 383-388
-
-
Cutler, C.1
Li, S.2
Kim, H.T.3
-
42
-
-
77953556313
-
A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis
-
Perkins J, Field T, Kim J, et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2010; 16: 937-47.
-
(2010)
Biol Blood Marrow Transplant
, vol.16
, pp. 937-947
-
-
Perkins, J.1
Field, T.2
Kim, J.3
-
43
-
-
20844450227
-
Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation
-
Mohty M, de Lavallade H, Faucher C, et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant. 2004; 34: 527-30.
-
(2004)
Bone Marrow Transplant
, vol.34
, pp. 527-530
-
-
Mohty, M.1
de Lavallade, H.2
Faucher, C.3
-
44
-
-
20844450608
-
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
-
Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005; 11: 495-505.
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 495-505
-
-
Nash, R.A.1
Johnston, L.2
Parker, P.3
-
45
-
-
2942718577
-
Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies
-
Rodriguez R, Parker P, Nademanee A, et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant. 2004; 33: 1123-9.
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 1123-1129
-
-
Rodriguez, R.1
Parker, P.2
Nademanee, A.3
-
46
-
-
67649601258
-
Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality
-
Sabry W, Le Blanc R, Labbe AC, et al. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality. Biol Blood Marrow Transplant. 2009; 15: 919-29.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 919-929
-
-
Sabry, W.1
Le Blanc, R.2
Labbe, A.C.3
-
47
-
-
77953051955
-
Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?
-
Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant. 2010; 16: S18-27.
-
(2010)
Biol Blood Marrow Transplant
, vol.16
-
-
Storb, R.1
Antin, J.H.2
Cutler, C.3
-
48
-
-
5044252176
-
A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation
-
Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 34: 621-5.
-
(2004)
Bone Marrow Transplant
, vol.34
, pp. 621-625
-
-
Bolwell, B.1
Sobecks, R.2
Pohlman, B.3
-
49
-
-
0344141613
-
Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation
-
Bornhauser M, Schuler U, Porksen G, et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999; 67: 499-504.
-
(1999)
Transplantation
, vol.67
, pp. 499-504
-
-
Bornhauser, M.1
Schuler, U.2
Porksen, G.3
-
50
-
-
0742306743
-
Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors
-
Kasper C, Sayer HG, Mugge LO, et al. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant. 2004; 33: 65-9.
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 65-69
-
-
Kasper, C.1
Sayer, H.G.2
Mugge, L.O.3
-
51
-
-
0034933004
-
Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings
-
Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant. 2001; 27: 1255-62.
-
(2001)
Bone Marrow Transplant
, vol.27
, pp. 1255-1262
-
-
Vogelsang, G.B.1
Arai, S.2
-
52
-
-
0037441604
-
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
-
Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003; 101: 1620-9.
-
(2003)
Blood
, vol.101
, pp. 1620-1629
-
-
Niederwieser, D.1
Maris, M.2
Shizuru, J.A.3
-
53
-
-
0035760863
-
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
-
Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001; 98: 3192-204.
-
(2001)
Blood
, vol.98
, pp. 3192-3204
-
-
Ho, V.T.1
Soiffer, R.J.2
-
54
-
-
0021330880
-
Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease
-
Filipovich AH, Vallera DA, Youle RJ, et al. Ex-vivo treatment of donor bone marrow with anti-T-cell immunotoxins for prevention of graft-versus-host disease. Lancet. 1984; 1: 469-72.
-
(1984)
Lancet
, vol.1
, pp. 469-472
-
-
Filipovich, A.H.1
Vallera, D.A.2
Youle, R.J.3
-
55
-
-
0026049124
-
T-cell depletion of HLA-identical transplants in leukemia
-
Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991; 78: 2120-30.
-
(1991)
Blood
, vol.78
, pp. 2120-2130
-
-
Marmont, A.M.1
Horowitz, M.M.2
Gale, R.P.3
-
56
-
-
69249193742
-
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
-
Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009; 10: 855-64.
-
(2009)
Lancet Oncol
, vol.10
, pp. 855-864
-
-
Finke, J.1
Bethge, W.A.2
Schmoor, C.3
-
57
-
-
0037444069
-
Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins
-
Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003; 75: 657-62.
-
(2003)
Transplantation
, vol.75
, pp. 657-662
-
-
Michallet, M.C.1
Preville, X.2
Flacher, M.3
-
58
-
-
0032055354
-
Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins
-
Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood. 1998; 91: 2360-8.
-
(1998)
Blood
, vol.91
, pp. 2360-2368
-
-
Genestier, L.1
Fournel, S.2
Flacher, M.3
-
59
-
-
84859631575
-
Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review
-
Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012; 26: 582-8.
-
(2012)
Leukemia
, vol.26
, pp. 582-588
-
-
Kumar, A.1
Mhaskar, A.R.2
Reljic, T.3
-
60
-
-
0032005216
-
T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease
-
Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood. 1998; 91: 1083-90.
-
(1998)
Blood
, vol.91
, pp. 1083-1090
-
-
Papadopoulos, E.B.1
Carabasi, M.H.2
Castro-Malaspina, H.3
-
61
-
-
39649110913
-
T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
-
Jakubowski AA, Small TN, Young JW, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood. 2007; 110: 4552-9.
-
(2007)
Blood
, vol.110
, pp. 4552-4559
-
-
Jakubowski, A.A.1
Small, T.N.2
Young, J.W.3
-
62
-
-
79960270124
-
Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303
-
Devine SM, Carter S, Soiffer RJ, et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011; 17: 1343-51.
-
(2011)
Biol Blood Marrow Transplant
, vol.17
, pp. 1343-1351
-
-
Devine, S.M.1
Carter, S.2
Soiffer, R.J.3
-
63
-
-
79960217520
-
T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies
-
Jakubowski AA, Small TN, Kernan NA, et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant. 2011; 17: 1335-42.
-
(2011)
Biol Blood Marrow Transplant
, vol.17
, pp. 1335-1342
-
-
Jakubowski, A.A.1
Small, T.N.2
Kernan, N.A.3
-
64
-
-
23944436856
-
Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial
-
Wagner JE, Thompson JS, Carter SL, et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet. 2005; 366: 733-41.
-
(2005)
Lancet
, vol.366
, pp. 733-741
-
-
Wagner, J.E.1
Thompson, J.S.2
Carter, S.L.3
-
65
-
-
33947591868
-
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution
-
Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007; 25: 690-7.
-
(2007)
J Clin Oncol
, vol.25
, pp. 690-697
-
-
Rizzieri, D.A.1
Koh, L.P.2
Long, G.D.3
-
66
-
-
10244242523
-
Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma
-
Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004; 104: 3865-71.
-
(2004)
Blood
, vol.104
, pp. 3865-3871
-
-
Morris, E.1
Thomson, K.2
Craddock, C.3
-
67
-
-
84863680262
-
Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease
-
Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012; 367: 135-45.
-
(2012)
N Engl J Med
, vol.367
, pp. 135-145
-
-
Reshef, R.1
Luger, S.M.2
Hexner, E.O.3
-
68
-
-
0037111657
-
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation
-
Antin JH, Weisdorf D, Neuberg D, et al. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 2002; 100: 3479-82.
-
(2002)
Blood
, vol.100
, pp. 3479-3482
-
-
Antin, J.H.1
Weisdorf, D.2
Neuberg, D.3
-
69
-
-
44649176508
-
Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
-
Hamadani M, Hofmeister CC, Jansak B, et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008; 14: 783-9.
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 783-789
-
-
Hamadani, M.1
Hofmeister, C.C.2
Jansak, B.3
-
70
-
-
84855613742
-
Novel treatment concepts for graft-versus-host disease
-
Wolf D, von Lilienfeld-Toal M, Wolf AM, et al. Novel treatment concepts for graft-versus-host disease. Blood. 2012; 119: 16-25.
-
(2012)
Blood
, vol.119
, pp. 16-25
-
-
Wolf, D.1
von Lilienfeld-Toal, M.2
Wolf, A.M.3
-
71
-
-
70449723162
-
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
-
Koreth J, Stevenson KE, Kim HT, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009; 114: 3956-9.
-
(2009)
Blood
, vol.114
, pp. 3956-3959
-
-
Koreth, J.1
Stevenson, K.E.2
Kim, H.T.3
-
72
-
-
0037025943
-
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation
-
Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002; 196: 389-99.
-
(2002)
J Exp Med
, vol.196
, pp. 389-399
-
-
Hoffmann, P.1
Ermann, J.2
Edinger, M.3
-
73
-
-
38349146500
-
The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation
-
Nguyen VH, Shashidhar S, Chang DS, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008; 111: 945-53.
-
(2008)
Blood
, vol.111
, pp. 945-953
-
-
Nguyen, V.H.1
Shashidhar, S.2
Chang, D.S.3
-
74
-
-
79953809817
-
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
-
Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011; 117: 3921-8.
-
(2011)
Blood
, vol.117
, pp. 3921-3928
-
-
Di Ianni, M.1
Falzetti, F.2
Carotti, A.3
-
75
-
-
78751696183
-
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics
-
Brunstein CG, Miller JS, Cao Q, et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011; 117: 1061-70.
-
(2011)
Blood
, vol.117
, pp. 1061-1070
-
-
Brunstein, C.G.1
Miller, J.S.2
Cao, Q.3
-
76
-
-
84862241567
-
Diagnosis and management of acute graft-versus-host disease
-
Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012; 158: 30-45.
-
(2012)
Br J Haematol
, vol.158
, pp. 30-45
-
-
Dignan, F.L.1
Clark, A.2
Amrolia, P.3
-
77
-
-
33947546893
-
Management of acute graft-versus-host disease
-
Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol. 2007; 137: 87-98.
-
(2007)
Br J Haematol
, vol.137
, pp. 87-98
-
-
Bacigalupo, A.1
-
78
-
-
0242291765
-
Immunobiology of acute graft-versus-host disease
-
Reddy P, Ferrara JL. Immunobiology of acute graft-versus-host disease. Blood Rev. 2003; 17: 187-94.
-
(2003)
Blood Rev
, vol.17
, pp. 187-194
-
-
Reddy, P.1
Ferrara, J.L.2
-
79
-
-
0016803914
-
Bone-marrow transplantation (first of two parts)
-
Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975; 292: 832-43.
-
(1975)
N Engl J Med
, vol.292
, pp. 832-843
-
-
Thomas, E.1
Storb, R.2
Clift, R.A.3
-
80
-
-
0027385129
-
Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial
-
Hings IM, Filipovich AH, Miller WJ, et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation. 1993; 56: 577-80.
-
(1993)
Transplantation
, vol.56
, pp. 577-580
-
-
Hings, I.M.1
Filipovich, A.H.2
Miller, W.J.3
-
81
-
-
84862137300
-
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
-
Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012; 18: 1150-63.
-
(2012)
Biol Blood Marrow Transplant
, vol.18
, pp. 1150-1163
-
-
Martin, P.J.1
Rizzo, J.D.2
Wingard, J.R.3
-
82
-
-
34248356010
-
How I treat refractory acute GVHD
-
Deeg HJ. How I treat refractory acute GVHD. Blood. 2007; 109: 4119-26.
-
(2007)
Blood
, vol.109
, pp. 4119-4126
-
-
Deeg, H.J.1
-
83
-
-
63849343227
-
Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes
-
Mielcarek M, Storer BE, Boeckh M, et al. Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood. 2009; 113: 2888-94.
-
(2009)
Blood
, vol.113
, pp. 2888-2894
-
-
Mielcarek, M.1
Storer, B.E.2
Boeckh, M.3
-
84
-
-
0025087325
-
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment
-
Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990; 76: 1464-72.
-
(1990)
Blood
, vol.76
, pp. 1464-1472
-
-
Martin, P.J.1
Schoch, G.2
Fisher, L.3
-
85
-
-
0025190044
-
Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome
-
Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood. 1990; 75: 1024-30.
-
(1990)
Blood
, vol.75
, pp. 1024-1030
-
-
Weisdorf, D.1
Haake, R.2
Blazar, B.3
-
86
-
-
0028100317
-
Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation
-
Hings IM, Severson R, Filipovich AH, et al. Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. Transplantation. 1994; 58: 437-42.
-
(1994)
Transplantation
, vol.58
, pp. 437-442
-
-
Hings, I.M.1
Severson, R.2
Filipovich, A.H.3
-
87
-
-
0036048349
-
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems
-
MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002; 8: 387-94.
-
(2002)
Biol Blood Marrow Transplant
, vol.8
, pp. 387-394
-
-
MacMillan, M.L.1
Weisdorf, D.J.2
Wagner, J.E.3
-
88
-
-
77955902702
-
The best endpoint for acute GVHD treatment trials
-
MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood. 2010; 115: 5412-7.
-
(2010)
Blood
, vol.115
, pp. 5412-5417
-
-
MacMillan, M.L.1
DeFor, T.E.2
Weisdorf, D.J.3
-
89
-
-
41349118744
-
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
-
Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008; 111: 2470-5.
-
(2008)
Blood
, vol.111
, pp. 2470-2475
-
-
Levine, J.E.1
Paczesny, S.2
Mineishi, S.3
-
90
-
-
70350567157
-
A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease
-
Couriel DR, Saliba R, de Lima M, et al. A phase III study of infliximab and corticosteroids for the initial treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009; 15: 1555-62.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 1555-1562
-
-
Couriel, D.R.1
Saliba, R.2
de Lima, M.3
-
91
-
-
0028860890
-
Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study
-
Cahn JY, Bordigoni P, Tiberghien P, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation. 1995; 60: 939-42.
-
(1995)
Transplantation
, vol.60
, pp. 939-942
-
-
Cahn, J.Y.1
Bordigoni, P.2
Tiberghien, P.3
-
92
-
-
4444304402
-
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
-
Lee SJ, Zahrieh D, Agura E, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004; 104: 1559-64.
-
(2004)
Blood
, vol.104
, pp. 1559-1564
-
-
Lee, S.J.1
Zahrieh, D.2
Agura, E.3
-
93
-
-
0034564569
-
A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease
-
Cragg L, Blazar BR, Defor T, et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant. 2000; 6: 441-7.
-
(2000)
Biol Blood Marrow Transplant
, vol.6
, pp. 441-447
-
-
Cragg, L.1
Blazar, B.R.2
Defor, T.3
-
94
-
-
70149109879
-
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
-
Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009; 114: 511-7.
-
(2009)
Blood
, vol.114
, pp. 511-517
-
-
Alousi, A.M.1
Weisdorf, D.J.2
Logan, B.R.3
-
95
-
-
66949170651
-
Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation
-
Pidala J, Kim J, Anasetti C. Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009; 15: 881-5.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 881-885
-
-
Pidala, J.1
Kim, J.2
Anasetti, C.3
-
97
-
-
33749986449
-
Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation
-
de Lavallade H, Mohty M, Faucher C, et al. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation. Haematologica. 2006; 91: 1438-40.
-
(2006)
Haematologica
, vol.91
, pp. 1438-1440
-
-
de Lavallade, H.1
Mohty, M.2
Faucher, C.3
-
98
-
-
3042612312
-
Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant
-
Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol. 2004; 73: 56-61.
-
(2004)
Eur J Haematol
, vol.73
, pp. 56-61
-
-
Kim, J.G.1
Sohn, S.K.2
Kim, D.H.3
-
99
-
-
27644507409
-
Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease
-
Krejci M, Doubek M, Buchler T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005; 84: 681-5.
-
(2005)
Ann Hematol
, vol.84
, pp. 681-685
-
-
Krejci, M.1
Doubek, M.2
Buchler, T.3
-
100
-
-
75049084631
-
Therapy with mycophenolate mofetil for refractory acute and chronic GVHD
-
Furlong T, Martin P, Flowers ME, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009; 44: 739-48.
-
(2009)
Bone Marrow Transplant
, vol.44
, pp. 739-748
-
-
Furlong, T.1
Martin, P.2
Flowers, M.E.3
-
101
-
-
77952429682
-
Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease
-
Pidala J, Kim J, Perkins J, et al. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. Bone Marrow Transplant. 2010; 45: 919-24.
-
(2010)
Bone Marrow Transplant
, vol.45
, pp. 919-924
-
-
Pidala, J.1
Kim, J.2
Perkins, J.3
-
102
-
-
0038345300
-
Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation
-
Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol. 2003; 122: 118-27.
-
(2003)
Br J Haematol
, vol.122
, pp. 118-127
-
-
Messina, C.1
Locatelli, F.2
Lanino, E.3
-
103
-
-
56349140988
-
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD
-
Perfetti P, Carlier P, Strada P, et al. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD. Bone Marrow Transplant. 2008; 42: 609-17.
-
(2008)
Bone Marrow Transplant
, vol.42
, pp. 609-617
-
-
Perfetti, P.1
Carlier, P.2
Strada, P.3
-
104
-
-
24944433163
-
Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease
-
Schmidt-Hieber M, Fietz T, Knauf W, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol. 2005; 130: 568-74.
-
(2005)
Br J Haematol
, vol.130
, pp. 568-574
-
-
Schmidt-Hieber, M.1
Fietz, T.2
Knauf, W.3
-
105
-
-
0035107591
-
Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab
-
Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol. 2001; 112: 820-3.
-
(2001)
Br J Haematol
, vol.112
, pp. 820-823
-
-
Willenbacher, W.1
Basara, N.2
Blau, I.W.3
-
106
-
-
0026442736
-
Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy
-
Cuthbert RJ, Phillips GL, Barnett MJ, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant. 1992; 10: 451-5.
-
(1992)
Bone Marrow Transplant
, vol.10
, pp. 451-455
-
-
Cuthbert, R.J.1
Phillips, G.L.2
Barnett, M.J.3
-
107
-
-
3843103590
-
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
-
Ho VT, Zahrieh D, Hochberg E, et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004; 104: 1224-6.
-
(2004)
Blood
, vol.104
, pp. 1224-1226
-
-
Ho, V.T.1
Zahrieh, D.2
Hochberg, E.3
-
108
-
-
14244265761
-
Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease
-
Shaughnessy PJ, Bachier C, Grimley M, et al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2005; 11: 188-93.
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 188-193
-
-
Shaughnessy, P.J.1
Bachier, C.2
Grimley, M.3
-
109
-
-
33947253595
-
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease
-
Macmillan ML, Couriel D, Weisdorf DJ, et al. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007; 109: 2657-62.
-
(2007)
Blood
, vol.109
, pp. 2657-2662
-
-
Macmillan, M.L.1
Couriel, D.2
Weisdorf, D.J.3
-
110
-
-
33646548277
-
Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin
-
Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006; 107: 4177-81.
-
(2006)
Blood
, vol.107
, pp. 4177-4181
-
-
Van Lint, M.T.1
Milone, G.2
Leotta, S.3
-
111
-
-
33845938451
-
Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation
-
Busca A, Locatelli F, Marmont F, et al. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007; 82: 45-52.
-
(2007)
Am J Hematol
, vol.82
, pp. 45-52
-
-
Busca, A.1
Locatelli, F.2
Marmont, F.3
-
112
-
-
21044442225
-
Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept
-
Wolff D, Roessler V, Steiner B, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant. 2005; 35: 1003-10.
-
(2005)
Bone Marrow Transplant
, vol.35
, pp. 1003-1010
-
-
Wolff, D.1
Roessler, V.2
Steiner, B.3
-
113
-
-
77955570085
-
Sirolimus for treatment of steroid-refractory acute graft-versus-host disease
-
Hoda D, Pidala J, Salgado-Vila N, et al. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant. 2010; 45: 1347-51.
-
(2010)
Bone Marrow Transplant
, vol.45
, pp. 1347-1351
-
-
Hoda, D.1
Pidala, J.2
Salgado-Vila, N.3
-
115
-
-
78651355835
-
Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective
-
Schub N, Gunther A, Schrauder A, et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective. Bone Marrow Transplant. 2011; 46: 143-7.
-
(2011)
Bone Marrow Transplant
, vol.46
, pp. 143-147
-
-
Schub, N.1
Gunther, A.2
Schrauder, A.3
-
116
-
-
3242756749
-
Tumor necrosis factor-alpha blockade for the treatment of acute GVHD
-
Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood. 2004; 104: 649-54.
-
(2004)
Blood
, vol.104
, pp. 649-654
-
-
Couriel, D.1
Saliba, R.2
Hicks, K.3
-
117
-
-
0030962344
-
A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT
-
Ruutu T, Niederwieser D, Gratwohl A, et al. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant. 1997; 19: 759-64.
-
(1997)
Bone Marrow Transplant
, vol.19
, pp. 759-764
-
-
Ruutu, T.1
Niederwieser, D.2
Gratwohl, A.3
-
118
-
-
0026757709
-
Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy
-
Roy J, McGlave PB, Filipovich AH, et al. Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. Bone Marrow Transplant. 1992; 10: 77-82.
-
(1992)
Bone Marrow Transplant
, vol.10
, pp. 77-82
-
-
Roy, J.1
McGlave, P.B.2
Filipovich, A.H.3
-
119
-
-
0025102027
-
Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation
-
Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990; 323: 705-12.
-
(1990)
N Engl J Med
, vol.323
, pp. 705-712
-
-
Sullivan, K.M.1
Kopecky, K.J.2
Jocom, J.3
-
120
-
-
17844362706
-
Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin
-
Khoury H, Kashyap A, Adkins DR, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant. 2001; 27: 1059-64.
-
(2001)
Bone Marrow Transplant
, vol.27
, pp. 1059-1064
-
-
Khoury, H.1
Kashyap, A.2
Adkins, D.R.3
-
121
-
-
2342482526
-
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
-
Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363: 1439-41.
-
(2004)
Lancet
, vol.363
, pp. 1439-1441
-
-
Le Blanc, K.1
Rasmusson, I.2
Sundberg, B.3
-
122
-
-
43049103438
-
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study
-
Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371: 1579-86.
-
(2008)
Lancet
, vol.371
, pp. 1579-1586
-
-
Le Blanc, K.1
Frassoni, F.2
Ball, L.3
-
123
-
-
33747371731
-
Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells
-
Fang B, Song YP, Liao LM, et al. Treatment of severe therapy-resistant acute graft-versus-host disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant. 2006; 38: 389-90.
-
(2006)
Bone Marrow Transplant
, vol.38
, pp. 389-390
-
-
Fang, B.1
Song, Y.P.2
Liao, L.M.3
-
124
-
-
33744913533
-
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
-
Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation. 2006; 81: 1390-7.
-
(2006)
Transplantation
, vol.81
, pp. 1390-1397
-
-
Ringden, O.1
Uzunel, M.2
Rasmusson, I.3
-
125
-
-
37049028974
-
Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease
-
Fang B, Song Y, Liao L, et al. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc. 2007; 39: 3358-62.
-
(2007)
Transplant Proc
, vol.39
, pp. 3358-3362
-
-
Fang, B.1
Song, Y.2
Liao, L.3
-
126
-
-
36749056828
-
Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation
-
Muller I, Kordowich S, Holzwarth C, et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. Blood Cells Mol Dis. 2008; 40: 25-32.
-
(2008)
Blood Cells Mol Dis
, vol.40
, pp. 25-32
-
-
Muller, I.1
Kordowich, S.2
Holzwarth, C.3
-
127
-
-
60349129494
-
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium
-
von Bonin M, Stolzel F, Goedecke A, et al. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium. Bone Marrow Transplant. 2009; 43: 245-51.
-
(2009)
Bone Marrow Transplant
, vol.43
, pp. 245-251
-
-
von Bonin, M.1
Stolzel, F.2
Goedecke, A.3
-
128
-
-
67149093649
-
Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease
-
Kebriaei P, Isola L, Bahceci E, et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009; 15: 804-11.
-
(2009)
Biol Blood Marrow Transplant
, vol.15
, pp. 804-811
-
-
Kebriaei, P.1
Isola, L.2
Bahceci, E.3
-
129
-
-
0037097836
-
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution
-
Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002; 99: 4357-63.
-
(2002)
Blood
, vol.99
, pp. 4357-4363
-
-
Chakrabarti, S.1
Mackinnon, S.2
Chopra, R.3
-
130
-
-
0036720393
-
Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery
-
Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002; 100: 1619-27.
-
(2002)
Blood
, vol.100
, pp. 1619-1627
-
-
Chakrabarti, S.1
Mautner, V.2
Osman, H.3
-
131
-
-
73949116753
-
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation
-
Bucher C, Koch L, Vogtenhuber C, et al. IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood. 2009; 114: 5375-84.
-
(2009)
Blood
, vol.114
, pp. 5375-5384
-
-
Bucher, C.1
Koch, L.2
Vogtenhuber, C.3
-
132
-
-
79960533396
-
Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL
-
Hanash AM, Kappel LW, Yim NL, et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood. 2011; 118: 446-55.
-
(2011)
Blood
, vol.118
, pp. 446-455
-
-
Hanash, A.M.1
Kappel, L.W.2
Yim, N.L.3
-
133
-
-
62849120700
-
Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance
-
Wang L, Tao R, Hancock WW. Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol. 2009; 87: 195-202.
-
(2009)
Immunol Cell Biol
, vol.87
, pp. 195-202
-
-
Wang, L.1
Tao, R.2
Hancock, W.W.3
-
134
-
-
17044374080
-
Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM)
-
Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood. 2005; 105: 3372-80.
-
(2005)
Blood
, vol.105
, pp. 3372-3380
-
-
Taylor, P.A.1
Panoskaltsis-Mortari, A.2
Freeman, G.J.3
-
135
-
-
84861820595
-
Antigen-presenting cell-derived complement modulates graft-versus-host disease
-
Kwan WH, Hashimoto D, Paz-Artal E, et al. Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest. 2012; 122: 2234-8.
-
(2012)
J Clin Invest
, vol.122
, pp. 2234-2238
-
-
Kwan, W.H.1
Hashimoto, D.2
Paz-Artal, E.3
-
136
-
-
79956068261
-
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation
-
Hashimoto D, Chow A, Greter M, et al. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med. 2011; 208: 1069-82.
-
(2011)
J Exp Med
, vol.208
, pp. 1069-1082
-
-
Hashimoto, D.1
Chow, A.2
Greter, M.3
-
137
-
-
84870897184
-
GSK3 inhibition prevents lethal GVHD in mice
-
e10.
-
Klamer G, Shen S, Song E, et al. GSK3 inhibition prevents lethal GVHD in mice. Exp Hematol. 2013; 41: 39-55 e10.
-
(2013)
Exp Hematol
, vol.41
, pp. 39-55
-
-
Klamer, G.1
Shen, S.2
Song, E.3
-
138
-
-
84873044177
-
Discovery and validation of graft-versus-host disease biomarkers
-
Paczesny S. Discovery and validation of graft-versus-host disease biomarkers. Blood. 2013; 121: 585-94.
-
(2013)
Blood
, vol.121
, pp. 585-594
-
-
Paczesny, S.1
-
139
-
-
65349157330
-
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study
-
Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009; 10: 489-500.
-
(2009)
Lancet Oncol
, vol.10
, pp. 489-500
-
-
Ciceri, F.1
Bonini, C.2
Stanghellini, M.T.3
-
140
-
-
34249688206
-
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation
-
Ciceri F, Bonini C, Marktel S, et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood. 2007; 109: 4698-707.
-
(2007)
Blood
, vol.109
, pp. 4698-4707
-
-
Ciceri, F.1
Bonini, C.2
Marktel, S.3
-
141
-
-
84877293011
-
Administration of hydrogen-rich saline protects mice from lethal acute graft-versus-host disease (aGVHD)
-
Qian L, Mei K, Shen J, et al. Administration of hydrogen-rich saline protects mice from lethal acute graft-versus-host disease (aGVHD). Transplantation. 2013; 95: 658-62.
-
(2013)
Transplantation
, vol.95
, pp. 658-662
-
-
Qian, L.1
Mei, K.2
Shen, J.3
-
142
-
-
84888199047
-
Hydrogen therapy may be an effective and specific novel treatment for Acute Graft-versus-host disease(GVHD)
-
doi: 10.1111/jcmm.12081.
-
Qian L, Shen J. Hydrogen therapy may be an effective and specific novel treatment for Acute Graft-versus-host disease(GVHD). J Cell Mol Med. 2013; doi: 10.1111/jcmm.12081.
-
(2013)
J Cell Mol Med
-
-
Qian, L.1
Shen, J.2
-
143
-
-
77951689048
-
Biological safety of neutral-pH hydrogen-enriched electrolyzed water upon mutagenicity, genotoxicity and subchronic oral toxicity
-
Saitoh Y, Harata Y, Mizuhashi F, et al. Biological safety of neutral-pH hydrogen-enriched electrolyzed water upon mutagenicity, genotoxicity and subchronic oral toxicity. Toxicol Ind Health. 2010; 26: 203-16.
-
(2010)
Toxicol Ind Health
, vol.26
, pp. 203-216
-
-
Saitoh, Y.1
Harata, Y.2
Mizuhashi, F.3
-
144
-
-
77949869116
-
Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study
-
Nakao A, Toyoda Y, Sharma P, et al. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. J Clin Biochem Nutr. 2010; 46: 140-9.
-
(2010)
J Clin Biochem Nutr
, vol.46
, pp. 140-149
-
-
Nakao, A.1
Toyoda, Y.2
Sharma, P.3
-
145
-
-
84864338677
-
Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia
-
Hamilton BK, Copelan EA. Concise review: the role of hematopoietic stem cell transplantation in the treatment of acute myeloid leukemia. Stem Cells. 2012; 30: 1581-6.
-
(2012)
Stem Cells
, vol.30
, pp. 1581-1586
-
-
Hamilton, B.K.1
Copelan, E.A.2
-
146
-
-
67651227639
-
Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation
-
Jones CV, Copelan EA. Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation. Future Oncol. 2009; 5: 559-68.
-
(2009)
Future Oncol
, vol.5
, pp. 559-568
-
-
Jones, C.V.1
Copelan, E.A.2
-
147
-
-
41949142667
-
Hematopoietic stem cell transplantation in adults with acute myeloid leukemia
-
Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2008; 14: 556-67.
-
(2008)
Biol Blood Marrow Transplant
, vol.14
, pp. 556-567
-
-
Hamadani, M.1
Awan, F.T.2
Copelan, E.A.3
-
148
-
-
34447315336
-
Hematopoietic stem cell transplantation in multiple myeloma
-
Pant S, Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2007; 13: 877-85.
-
(2007)
Biol Blood Marrow Transplant
, vol.13
, pp. 877-885
-
-
Pant, S.1
Copelan, E.A.2
-
149
-
-
33646119401
-
Hematopoietic stem-cell transplantation
-
Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354: 1813-26.
-
(2006)
N Engl J Med
, vol.354
, pp. 1813-1826
-
-
Copelan, E.A.1
-
150
-
-
84859173432
-
History of hematopoietic stem cell transplantation: evolution and perspectives
-
Gratwohl A, Niederwieser D. History of hematopoietic stem cell transplantation: evolution and perspectives. Curr Probl Dermatol. 2012; 43: 81-90.
-
(2012)
Curr Probl Dermatol
, vol.43
, pp. 81-90
-
-
Gratwohl, A.1
Niederwieser, D.2
|